Latest News

Filters

Filter by tags: Netherlands Melanoma Clear all tag filters

1 news articles found


Advances in emerging field of ‘theranostics’ are a game-changer Millions of patients around the globe rely on the regular and timely production of diagnostic and therapeutic isotopes produced in research reactors and accelerator facilities. Image courtesy IAEA. Advances in medical isotope diagnostics and therapy are holding promise for cancer patients, despite challenges facing the nuclear medical field in recent years related to radionuclide production and supply, rising costs, and stricter regulation.

Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.

Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.

According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.

Date: Friday, 14 April 2023
Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023